Perspective Therapeutics (CATX) Cash from Operations (2010 - 2026)
Perspective Therapeutics (CATX) posted Cash from Operations of 31468000.0 for Q1 2026, down 27.62% sequentially from 24657000.0 in Q4 2025, and down 45.81% YoY from 58066208.62 in Q1 2025.
Perspective Therapeutics (CATX) Cash from Operations (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Cash from Operations for 17 years, with the latest figure at 31468000.0 in Q1 2026.
- Quarterly Cash from Operations fell 45.81% year-over-year to 31468000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 92370000.0 (down 71.93% YoY) and the FY2025 annual result came in at 82484000.0, down 350.88% from the prior year.
- Cash from Operations eased to 31468000.0 in Q1 2026 per CATX's latest filing, from 24657000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 13848000.0 in Q1 2024 and troughed at 31468000.0 in Q1 2026.
- A 5-year average of 11003647.06 and a median of 9008000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations soared 242.43% in 2024, then tumbled 584.02% in 2025.
- Over 5 years, Cash from Operations stood at 6086000.0 in 2022, then tumbled by 48.01% to 9008000.0 in 2023, then slumped by 195.36% to 26606000.0 in 2024, then increased by 7.33% to 24657000.0 in 2025, then fell by 27.62% to 31468000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 31468000.0, 24657000.0, and 16292000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 2.49 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 1.26 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 2.57 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 1.47 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 651.90 Mn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 269.20 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 168.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 437.05 Mn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 367.10 Mn |
| 10 | Perspective Therapeutics | 389.10 Mn | 389.10 Mn | - | -20.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.65 Mn |
| Jun 30, 2026 | -20.65 Mn |
| Mar 31, 2026 | -31.47 Mn |
| Mar 31, 2026 | -31.47 Mn |
| Dec 31, 2025 | -24.66 Mn |
| Dec 31, 2025 | -24.66 Mn |
| Sep 30, 2025 | -16.29 Mn |
| Sep 30, 2025 | -16.29 Mn |
| Jun 30, 2025 | -19.95 Mn |
| Jun 30, 2025 | -19.95 Mn |
| Mar 31, 2025 | -21.58 Mn |
| Mar 31, 2025 | -21.58 Mn |
| Dec 31, 2024 | -26.61 Mn |
| Dec 31, 2024 | -26.61 Mn |
| Sep 30, 2024 | 3.37 Mn |
| Sep 30, 2024 | 3.37 Mn |
| Jun 30, 2024 | -8.90 Mn |
| Jun 30, 2024 | -8.90 Mn |
| Mar 31, 2024 | 13.85 Mn |
| Mar 31, 2024 | 13.85 Mn |